Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 June 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Post-transplant lymphoproliferative risk in pancreas recipients

Post-transplant lymphoproliferative in pancreas recipients has a worse prognosis than in other transplant recipients, and these immunosuppressed patients, who often face multiple transplants, may be at greater risk, reports the latest Transplantation.

News image

fiogf49gjkf04

Post-transplant lymphoproliferative disorder is a rare, serious complication of transplantation.

The characteristics and associations of this disease in pancreas recipients have not been extensively studied.

Dr Steven Paraskevas and colleagues performed 787 pancreas and 569 kidney-pancreas transplants from 1988 to 2002 at their institution.

The research team reported that 18 pancreas recipients developed polymorphic posttransplant lymphoproliferative disorder or malignant lymphoma.

Data on clinical course, organ involvement, molecular characteristics was compiled from the institutional transplant database

Cytomegalovirus infection may play an antecedent role
Transplantation

The researchers also compiled data on and association with immunosuppression and recent cytomegalovirus infection.

Patient survival was compared to recipients of liver and kidney transplants at the same center by using Kaplan-Meier analysis.

The researchers found that the 5-year cumulative incidence of posttransplant lymphoproliferative in simultaneous pancreas-kidney recipients was 3%.

The 5-year cumulative incidence of post-transplant lymphoproliferative in pancreas after kidney recipients was 1.2%.

In pancreas transplant alone recipients, the 5-year cumulative incidence of the disease was 1%.

The team noticed a higher, but not significant, cumulative incidence in the more recent era since 1995.

Post-transplant lymphoproliferative in pancreas recipients carried a worse prognosis than in liver or kidney for recipients B-cell.

The researchers also observed that Post-transplant lymphoproliferative had a worse prognosis with early-onset, and Epstein Barr virus-positive lesions.

Posttransplant lymphoproliferative was more aggressive in pancreas recipients, with a higher stage at presentation and a trend to more bone marrow involvement.

The research team noted a tendency toward association with recent cytomegalovirus infection.

Since 1995, the team observed that post-transplant lymphoproliferative recipients have had a lower exposure to antilymphocyte preparations.

Dr Paraskevas' team concludes, “Posttransplant lymphoproliferative in pancreas recipients remains a rare but aggressive disease, and carries a worse prognosis in comparison to other transplant recipients.”

“These heavily immunosuppressed patients, who often face multiple transplants, may be at greater risk; cytomegalovirus infection may play an antecedent role.”

Transpl 2005: 80(5) 613-22
22 September 2005

Go to top of page Email this page Email this page to a colleague

 23 June 2017 
Treatment for KRAS wild-type advanced colorectal cancer
 23 June 2017 
Epidemiology of Hep E
 23 June 2017 
Predictive model for clinical course of Crohn's disease
 22 June 2017 
Vonoprazan-based triple therapy on H. pylori eradication
 22 June 2017 
Adolescent transition in IBD
 22 June 2017 
Patient understanding of biologic therapy in IBD
 21 June 2017 
Hydrolyzed wheat flour improves immunogenicity in celiac disease
 21 June 2017 
Statins in chronic Hep C
 21 June 2017 
Racial disparities in colorectal cancer
 20 June 2017 
Therapies in chronic pancreatitis
 20 June 2017 
Genetic analyses for malignancy detection in biliary strictures
 20 June 2017 
Viral-associated esophagus cancers
 19 June 2017 
Global prevalence of IBS in adults
 19 June 2017 
Clinical improvement in mild acute pancreatitis
 19 June 2017 
Repeat biopsy and celiac disease outcomes 
 16 June 2017 
Exercise-induced GI syndrome—implications for intestinal disease
 16 June 2017 
HCV among reproductive-aged women and children in the USA
 16 June 2017 
Adverse events after outpatient colonoscopy
 15 June 2017 
Pioglitazone for NASH
 15 June 2017 
Urinary adverse events after rectal cancer treatment
 15 June 2017 
Treatment of eosinophilic esophagitis
 14 June 2017 
Genetics of familial colorectal cancer
 14 June 2017 
Abdominal ultrasound in blunt torso trauma
 14 June 2017 
Acute kidney injury in Hep C and sofosbuvir-based regimens
 13 June 2017 
Serrated polyps in the colon and rectum
 13 June 2017 
Colorectal cancer during pregnancy
 13 June 2017 
Biomarker for penetrating Crohn's
 12 June 2017 
Course of primary sclerosing cholangitis
 12 June 2017 
Quality of life in end-stage liver disease
 12 June 2017 
Clinical remission in patients with Crohn's disease
 09 June 2017 
Socioeconomic influences on H. pylori gastritis
 09 June 2017 
Celiac disease in Ireland
 09 June 2017 
Consultants do not follow up on GI tests they recommend
 08 June 2017 
Genetics and the gut microbiota and metabolic syndrome
 08 June 2017 
Antireflux surgery in extraesophageal reflux
 08 June 2017 
Breath testing in gastrointestinal disorders
 07 June 2017 
Multidisciplinary care and liver cancer
 07 June 2017 
Model for excluding NAFLD
 07 June 2017 
Hospital readmission in IBD
 06 June 2017 
Dietary patterns and colorectal cancer risk
 06 June 2017 
Direct-acting antiviral agents for HCV
 06 June 2017 
Medical therapies for stricturing Crohn’s
 05 June 2017 
Celiac disease prevalence in the USA
 05 June 2017 
Hospital-acquired conditions in Crohn’s disease
 05 June 2017 
Depression and IBD
 02 June 2017 
Menopausal hormone therapy and fecal incontinence
 02 June 2017 
Narcotic and corticosteroid prescriptions in IBD
 02 June 2017 
Treating anemia after gastrectomy
 01 June 2017 
Infliximab and cancer in pediatric IBD
 01 June 2017 
Health insurance policies in IBD
 01 June 2017 
Endoscopic quality improvement program for polyp detection
 31 May 2017 
Probiotics and Clostridium difficile infection
 31 May 2017 
Post-procedural adverse events after colonoscopy
 31 May 2017 
Clinical decision-making in severe alcoholic hepatitis
 30 May 2017 
Waist belts and reflux
 30 May 2017 
Colorectal cancer increases in developed and developing regions
 30 May 2017 
Antidepressants and bleeding in peptic ulcers
 26 May 2017 
Accreditation program for rectal cancer
 26 May 2017 
Risk of lower GI bleeds with aspirin
 26 May 2017 
Adverse events after outpatient colonoscopy in high-risk patients

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us